Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation IV: Nursing Management01:17

Aortic Regurgitation IV: Nursing Management

A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nature-based solutions and indigenous knowledge for sustainable biological control.

Current opinion in insect science·2026
Same author

Stent Edge-Related Hematoma: An Overlooked Predictor of Early Stent Failure.

JACC. Cardiovascular interventions·2026
Same author

Efficacy of the Shear Stress Pattern Computed in Coronary Artery Reconstruction Models With and Without Side Branches in Predicting Plaque Progression.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Tumour acquisition method and molecular profiling success in advanced cholangiocarcinoma.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation　- Post Hoc Analysis of the PACMAN-AMI Study.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

A novel framework for fully automated co-registration of intravascular ultrasound and optical coherence tomography imaging data.

European heart journal. Digital health·2026
Same journal

Comparing transcatheter aortic valves: time to look beyond simplistic categorisations.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same journal

Validation of the VARC-HBR consensus for defining high bleeding risk in TAVI.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same journal

Concomitant transfemoral aortic and mitral valve replacement.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same journal

AnchorMan versus Watchman 2.5: a randomised comparison in left atrial appendage closure.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same journal

Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same journal

Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Transcatheter aortic valve update 2013.

Christos V Bourantas1, Nicolas M Van Mieghem, Osama Soliman

  • 1ThoraxCenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|September 13, 2013
PubMed
Summary
This summary is machine-generated.

Transcatheter aortic valve implantation (TAVI) is an effective treatment for severe aortic stenosis in high-risk patients. Advances in TAVI technology improve outcomes and expand its use, with ongoing research addressing remaining limitations.

Related Experiment Videos

Last Updated: May 8, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Severe symptomatic aortic stenosis poses significant risks for high-operative-risk patients.
  • Transcatheter aortic valve implantation (TAVI) has emerged as a crucial treatment modality.
  • Technological advancements are continuously refining TAVI procedures.

Purpose of the Study:

  • To review the current evidence and advancements in TAVI.
  • To discuss the benefits, potential, and limitations of TAVI.
  • To highlight strategies for addressing TAVI's challenges.

Main Methods:

  • Review of cumulative evidence and global adoption data of TAVI.
  • Analysis of new valve designs and TAVI-enabling devices.
  • Discussion of patient selection and risk stratification for TAVI.

Main Results:

  • TAVI is an effective treatment for severe symptomatic aortic stenosis in high-risk individuals.
  • Innovations in valve design and enabling technologies have enhanced TAVI safety and efficacy.
  • Global TAVI adoption provides insights into its advantages and limitations.

Conclusions:

  • TAVI represents a vital therapeutic option, with ongoing innovation expanding its applicability.
  • Accurate patient selection and risk assessment are key to optimizing TAVI outcomes.
  • Further developments are focused on overcoming TAVI's inherent limitations.